Comprehensive Hypertension Diagnosis and Drug Prescription Algorithm for Indian Government Hospital OPD
1. BP CLASSIFICATION, MEASUREMENT & DIAGNOSIS
Correct BP Measurement Technique
Use a validated automated upper arm cuff device with appropriate cuff size 1. At the first visit, measure BP in both arms simultaneously; if there is a consistent difference, always use the arm with the higher reading 1.
Office BP measurement requires the average of 2 readings 1. If office BP ≥140/90 mmHg, remeasure in 2-3 office visits 1.
BP Classification (ISH 2020)
- Normal BP: <130/85 mmHg → Remeasure after 3 years 1
- High-normal BP: 130-139/85-89 mmHg → Take 2 more readings 1
- Grade 1 Hypertension: 140-159/90-99 mmHg 1
- Grade 2 Hypertension: ≥160/100 mmHg 1
Confirmation of Hypertension
Repeated office BP ≥140/90 mmHg indicates hypertension, particularly if confirmed by home BP ≥135/85 mmHg or 24-hour ambulatory BP ≥130/80 mmHg 1. In resource-limited Indian government OPD settings where ABPM may not be available, confirm with home BP monitoring using validated devices 2.
2. BASELINE INVESTIGATIONS & RISK STRATIFICATION
Essential Baseline Tests
- Fasting blood glucose and HbA1c (diabetes screening)
- Serum creatinine and eGFR (CKD assessment)
- Serum potassium (baseline before starting RAS blockers or diuretics)
- Lipid profile (cardiovascular risk)
- Urine albumin-to-creatinine ratio (target organ damage)
- ECG (left ventricular hypertrophy, ischemia)
Target Organ Damage Assessment
Look for:
- Cardiac: LVH on ECG, history of MI, angina, heart failure
- Renal: eGFR <60 mL/min/1.73m², albuminuria (>30 mg/g)
- Vascular: History of stroke, TIA, peripheral arterial disease
- Retinal: Fundoscopy if available (hypertensive retinopathy)
Secondary Hypertension Red Flags
Refer for specialist evaluation if:
- Age <30 years with hypertension
- Resistant hypertension (uncontrolled on 3 drugs including diuretic)
- Hypokalemia (unprovoked or diuretic-induced <3.0 mEq/L)
- Abdominal bruit (renal artery stenosis)
- Variable BP with headaches, palpitations, sweating (pheochromocytoma)
3. WHEN TO START MEDICATION VS. LIFESTYLE MODIFICATION ALONE
Start Drug Treatment IMMEDIATELY in: 1
- Grade 2 Hypertension (≥160/100 mmHg) — all patients
- Grade 1 Hypertension (140-159/90-99 mmHg) with ANY of:
- High-risk patients: CVD, CKD, diabetes, target organ damage, or aged 50-80 years 1
Lifestyle Modification Alone (3-6 months trial) in: 1
- Grade 1 Hypertension (140-159/90-99 mmHg) in low-moderate risk patients without diabetes, CKD, CVD, or organ damage
- If BP remains ≥140/90 mmHg after 3-6 months, start drug therapy 1
Lifestyle Modifications (All Patients)
- Dietary sodium restriction: <5 g/day (1 teaspoon salt)
- DASH diet: Increase fruits, vegetables, whole grains
- Weight loss: Target BMI <25 kg/m² (or <23 kg/m² for Indians)
- Physical activity: 150 minutes/week moderate aerobic exercise
- Alcohol limitation: ≤2 drinks/day (men), ≤1 drink/day (women)
- Smoking cessation
4. FIRST-LINE ANTIHYPERTENSIVE DRUGS: EXACT DOSES & TITRATION
The four first-line drug classes are: ACE inhibitors, ARBs, dihydropyridine CCBs, and thiazide/thiazide-like diuretics 1, 3. Beta-blockers are NOT first-line unless there are compelling indications 3.
ACE Inhibitors (ACEi)
| Drug | Starting Dose | Maximum Dose | Frequency |
|---|---|---|---|
| Enalapril | 5 mg | 40 mg | Once or twice daily |
| Ramipril | 2.5 mg | 10 mg | Once daily |
| Lisinopril | 5-10 mg | 40 mg | Once daily |
| Perindopril | 4 mg | 8 mg | Once daily |
Titration: Increase dose every 2-4 weeks if BP not at target.
Contraindications: Pregnancy, bilateral renal artery stenosis, history of angioedema, hyperkalemia (K+ >5.5 mEq/L).
Adverse Effects: Dry cough (10-15%), hyperkalemia, acute kidney injury (monitor creatinine at 1-2 weeks), angioedema (rare but serious).
Monitoring: Check serum creatinine and potassium at 1-2 weeks after initiation or dose increase. Accept up to 30% rise in creatinine; if >30%, consider renal artery stenosis.
Angiotensin Receptor Blockers (ARBs)
| Drug | Starting Dose | Maximum Dose | Frequency |
|---|---|---|---|
| Telmisartan | 40 mg | 80 mg | Once daily |
| Losartan | 50 mg | 100 mg | Once or twice daily |
| Olmesartan | 20 mg | 40 mg | Once daily |
| Azilsartan | 40 mg | 80 mg | Once daily |
Titration: Increase dose every 2-4 weeks if BP not at target.
Contraindications: Same as ACEi (pregnancy, bilateral renal artery stenosis, hyperkalemia).
Adverse Effects: Similar to ACEi but no cough (preferred if ACEi-induced cough). Hyperkalemia, dizziness, acute kidney injury.
Monitoring: Same as ACEi—check creatinine and potassium at 1-2 weeks.
Indian Context: Telmisartan is widely available and cost-effective in India 4.
Dihydropyridine Calcium Channel Blockers (DHP-CCBs)
| Drug | Starting Dose | Maximum Dose | Frequency |
|---|---|---|---|
| Amlodipine | 5 mg | 10 mg | Once daily |
| Cilnidipine | 10 mg | 20 mg | Once daily |
| Nifedipine (extended-release) | 30 mg | 90 mg | Once daily |
Titration: Increase dose every 2-4 weeks if BP not at target.
Contraindications: Severe aortic stenosis, decompensated heart failure (use with caution in HFrEF).
Adverse Effects: Peripheral edema (10-30%), flushing, headache, gingival hyperplasia. Combining with ACEi/ARB reduces edema 5.
Indian Context: Cilnidipine is increasingly recommended in Indian guidelines for diabetic hypertension due to dual N-type and L-type calcium channel blockade, offering renal and cardiac protection 2, 4. It may reduce proteinuria more effectively than amlodipine in diabetic patients 4.
Thiazide and Thiazide-Like Diuretics
| Drug | Starting Dose | Maximum Dose | Frequency |
|---|---|---|---|
| Chlorthalidone | 12.5 mg | 25 mg | Once daily (morning) |
| Indapamide | 1.5 mg SR | 1.5 mg SR | Once daily (morning) |
| Hydrochlorothiazide (HCTZ) | 12.5 mg | 25 mg | Once daily (morning) |
Titration: Increase dose after 4 weeks if BP not at target. Do not exceed maximum doses (higher doses increase side effects without additional BP benefit).
Contraindications: Gout, severe hypokalemia, hyponatremia.
Adverse Effects: Hypokalemia, hyponatremia, hyperuricemia (gout), hyperglycemia, hyperlipidemia, erectile dysfunction.
Monitoring: Check serum potassium, sodium, creatinine, and uric acid at 2-4 weeks after initiation.
Preference: Chlorthalidone and indapamide are preferred over HCTZ due to longer half-life and superior cardiovascular outcomes 5. However, HCTZ is more widely available in Indian government hospitals.
Beta-Blockers (NOT First-Line)
Beta-blockers should be reserved for compelling indications 3:
- Post-myocardial infarction
- Heart failure with reduced ejection fraction (HFrEF)
- Angina pectoris
- Atrial fibrillation (rate control)
- Younger patients with hyperadrenergic state
| Drug | Starting Dose | Maximum Dose | Frequency |
|---|---|---|---|
| Metoprolol succinate (extended-release) | 25-50 mg | 200 mg | Once daily |
| Bisoprolol | 2.5 mg | 10 mg | Once daily |
| Carvedilol | 6.25 mg | 25 mg | Twice daily |
| Atenolol | 25 mg | 100 mg | Once daily |
Contraindications: Asthma, COPD with bronchospasm, severe bradycardia (<50 bpm), second- or third-degree AV block, decompensated heart failure.
Adverse Effects: Bradycardia, fatigue, erectile dysfunction, bronchospasm, masking hypoglycemia (in diabetics), worsening peripheral arterial disease.
Monitoring: Heart rate, BP, symptoms of bronchospasm or heart failure.
5. STEP-BY-STEP TREATMENT ESCALATION ALGORITHM
Target BP: <140/90 mmHg for most patients; <130/80 mmHg for high-risk patients (diabetes, CKD, CVD) 1, 3. Achieve target within 3 months 1.
STEP 1: MONOTHERAPY vs. INITIAL COMBINATION THERAPY
Monotherapy (Low-Risk Grade 1 Hypertension, Age >80 years, Frail Patients) 1, 3
Non-Black Patients:
- Start low-dose ACEi or ARB 1
- Example: Tab. Telmisartan 40 mg once daily or Tab. Ramipril 2.5 mg once daily
Black Patients (or South Indian populations with African ancestry):
- Start low-dose ARB or DHP-CCB 1
- Example: Tab. Telmisartan 40 mg once daily or Tab. Amlodipine 5 mg once daily
Initial Combination Therapy (Preferred for Most Patients) 5, 3
For Grade 2 Hypertension (≥160/100 mmHg) or high-risk Grade 1 Hypertension (diabetes, CKD, CVD), start with dual combination therapy 5, 3.
Preferred Combinations:
- RAS blocker (ACEi or ARB) + DHP-CCB
- RAS blocker (ACEi or ARB) + Thiazide/Thiazide-like diuretic
Example Prescriptions:
- Tab. Telmisartan 40 mg + Amlodipine 5 mg once daily (single-pill combination preferred) 3
- Tab. Ramipril 2.5 mg + Chlorthalidone 12.5 mg once daily
Rationale: Combination therapy achieves BP control faster, improves adherence (especially with single-pill combinations), and reduces side effects (e.g., ACEi/ARB reduces CCB-induced edema) 5, 3.
STEP 2: INCREASE TO FULL DOSE OR ADD SECOND DRUG
If BP not at target after 2-4 weeks:
If started on monotherapy:
- Increase to full dose of initial drug 1
- Example: Telmisartan 40 mg → 80 mg once daily
OR add a second drug from a different class:
If started on dual combination:
- Increase both drugs to full dose 1
- Example: Telmisartan 40 mg + Amlodipine 5 mg → Telmisartan 80 mg + Amlodipine 10 mg
STEP 3: TRIPLE THERAPY
If BP not controlled on dual therapy at full doses, add a third drug 1, 3.
Standard Triple Combination:
Example Prescription:
- Tab. Telmisartan 80 mg + Amlodipine 10 mg + Chlorthalidone 12.5 mg once daily (single-pill combination preferred if available) 3
Alternative if single-pill not available:
- Tab. Telmisartan 80 mg once daily
- Tab. Amlodipine 10 mg once daily
- Tab. Chlorthalidone 12.5 mg once daily (morning)
STEP 4: RESISTANT HYPERTENSION (Uncontrolled on Triple Therapy)
Definition: BP ≥140/90 mmHg despite adherence to triple therapy (RAS blocker + CCB + diuretic) at optimal doses 1.
Before escalating, confirm:
- Medication adherence (most common cause of apparent resistance)
- White-coat hypertension (confirm with home BP or ABPM)
- Secondary hypertension (refer for specialist evaluation)
STEP 4A: Add Spironolactone 1, 3
- Tab. Spironolactone 25 mg once daily (morning)
- Increase to 50 mg once daily if needed after 4 weeks
- Monitor potassium closely (risk of hyperkalemia, especially with ACEi/ARB)
- Check potassium at 1 week, then monthly for 3 months
Contraindications: Hyperkalemia (K+ >5.0 mEq/L), severe renal impairment (eGFR <30 mL/min), pregnancy.
Adverse Effects: Hyperkalemia, gynecomastia (men), menstrual irregularities (women).
STEP 4B: If Spironolactone Not Tolerated or Contraindicated 1
Add one of the following:
- Eplerenone 50 mg once daily (selective mineralocorticoid receptor antagonist, less gynecomastia)
- Amiloride 5-10 mg once daily (potassium-sparing diuretic)
- Doxazosin 1-8 mg once daily (alpha-blocker; start low due to orthostatic hypotension risk)
- Beta-blocker (if not already on one): Metoprolol succinate 25-100 mg once daily
- Clonidine 0.1-0.3 mg twice daily (centrally acting agent; avoid abrupt discontinuation—rebound hypertension)
Refer to hypertension specialist if BP remains uncontrolled 1.
6. DRUG SELECTION BASED ON COMORBIDITIES
Diabetes Mellitus (Type 2) 2, 6
First-Line: ACEi or ARB + DHP-CCB (preferably cilnidipine in India) 2, 4
Rationale: ACEi/ARB provide renoprotection (reduce albuminuria, slow CKD progression). Cilnidipine offers additional renal and cardiac benefits in diabetic patients 2, 4.
Example Prescription:
- Tab. Telmisartan 40 mg + Cilnidipine 10 mg once daily
Avoid: Beta-blockers (mask hypoglycemia, worsen insulin resistance) unless compelling indication (post-MI, HFrEF) 2.
Additional Considerations:
- SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) provide cardio- and renoprotection in diabetic hypertension 2, 6. Consider adding if eGFR ≥20 mL/min.
- Finerenone (non-steroidal mineralocorticoid receptor antagonist) reduces cardiovascular and renal events in diabetic CKD 2, 6.
Chronic Kidney Disease (CKD) 6
First-Line: ACEi or ARB (renoprotection, reduce proteinuria) 6
Example Prescription:
- Tab. Ramipril 5 mg once daily or Tab. Telmisartan 40 mg once daily
Add: DHP-CCB or thiazide-like diuretic (if eGFR ≥30 mL/min) or loop diuretic (if eGFR <30 mL/min) 6.
Monitoring: Check creatinine and potassium at 1-2 weeks. Accept up to 30% rise in creatinine. If >30%, consider bilateral renal artery stenosis.
Renal Dose Adjustments:
- Enalapril: Reduce dose if eGFR <30 mL/min
- Ramipril: Reduce dose if eGFR <30 mL/min
- Telmisartan: No dose adjustment needed
- Amlodipine: No dose adjustment needed
- Chlorthalidone: Ineffective if eGFR <30 mL/min; switch to loop diuretic (furosemide 40-80 mg twice daily)
Avoid: NSAIDs (worsen renal function, reduce ACEi/ARB efficacy).
Target BP: <130/80 mmHg 6
Heart Failure with Reduced Ejection Fraction (HFrEF) 6
First-Line: ACEi or ARB + Beta-blocker + Diuretic 6
Example Prescription:
- Tab. Ramipril 2.5 mg once daily (titrate to 10 mg)
- Tab. Bisoprolol 2.5 mg once daily (titrate to 10 mg)
- Tab. Furosemide 40 mg once daily (adjust based on volume status)
Add: Spironolactone 25 mg once daily (proven mortality benefit in HFrEF) 6.
Avoid: Non-dihydropyridine CCBs (diltiazem, verapamil) in HFrEF—negative inotropic effect.
DHP-CCBs (amlodipine) are safe in HFrEF if needed for BP control 6.
Target BP: <130/80 mmHg 6
Coronary Artery Disease (CAD) / Post-Myocardial Infarction 6
First-Line: Beta-blocker + ACEi or ARB 6
Example Prescription:
- Tab. Metoprolol succinate 50 mg once daily (titrate to 200 mg)
- Tab. Ramipril 5 mg once daily (titrate to 10 mg)
Add: DHP-CCB (amlodipine) if additional BP control needed 6.
Avoid: Short-acting nifedipine (increases myocardial ischemia).
Target BP: <130/80 mmHg 6
Pregnancy 7
CRITICAL: ACEi, ARBs, and spironolactone are ABSOLUTELY CONTRAINDICATED in pregnancy (teratogenic) 7.
Safe Antihypertensives in Pregnancy:
- Methyldopa 250-500 mg twice or thrice daily (first-line)
- Labetalol 100-400 mg twice daily (beta-blocker with alpha-blocking activity)
- Nifedipine (extended-release) 30-60 mg once daily
Severe Hypertension in Pregnancy (≥160/110 mmHg):
- IV Labetalol 20 mg bolus, then 20-80 mg every 10 minutes (max 300 mg)
- OR IV Hydralazine 5 mg bolus, then 5-10 mg every 20 minutes (max 20 mg)
- OR Oral Nifedipine immediate-release 10 mg, repeat every 20 minutes (max 30 mg)
Target BP in Pregnancy: 130-150/80-100 mmHg (avoid excessive lowering—placental hypoperfusion) 7.
Refer immediately to obstetrics for preeclampsia management (delivery is definitive treatment) 7.
Elderly (Age >80 years) and Frail Patients 1, 3
Start with monotherapy at low doses 1, 3. Slower titration to avoid orthostatic hypotension.
Example Prescription:
- Tab. Amlodipine 2.5 mg once daily (increase to 5 mg after 4 weeks if tolerated)
Target BP: <150/90 mmHg (less stringent target to avoid falls and hypoperfusion) 1, 3.
Monitor for: Orthostatic hypotension (measure BP sitting and standing), falls, dizziness.
Age <50 years (Young Hypertension) 8
Preferred: ACEi or ARB (reduce long-term cardiovascular and renal risk) 8.
Example Prescription:
- Tab. Ramipril 2.5 mg once daily
Screen for secondary hypertension (more common in young patients).
7. CONTRAINDICATIONS, ADVERSE EFFECTS, INTERACTIONS & MONITORING
Dangerous Drug Combinations to AVOID
ACEi + ARB + Renin Inhibitor (e.g., aliskiren): Increased risk of hyperkalemia, hypotension, acute kidney injury, and mortality 5, 3. NEVER combine two RAS blockers.
ACEi/ARB + Spironolactone in severe CKD (eGFR <30 mL/min): High risk of life-threatening hyperkalemia. If used, monitor potassium weekly initially.
Beta-blocker + Non-DHP CCB (diltiazem, verapamil): Risk of severe bradycardia and heart block. Avoid this combination.
NSAIDs + ACEi/ARB + Diuretic ("Triple Whammy"): Increased risk of acute kidney injury. Avoid NSAIDs in hypertensive patients on RAS blockers and diuretics.
Short-acting nifedipine in acute coronary syndrome: Reflex tachycardia worsens ischemia. Use extended-release formulations only.
Electrolyte Monitoring
| Drug Class | Electrolyte Concern | Monitoring Schedule |
|---|---|---|
| ACEi/ARB | Hyperkalemia | K+ and creatinine at 1-2 weeks, then every 3-6 months |
| Thiazide/Thiazide-like diuretics | Hypokalemia, hyponatremia | K+, Na+, creatinine at 2-4 weeks, then every 3-6 months |
| Spironolactone | Hyperkalemia | K+ at 1 week, then monthly for 3 months, then every 3 months |
| Loop diuretics | Hypokalemia, hypomagnesemia | K+, Mg2+ every 1-3 months |
Common Adverse Effects & Management
| Drug Class | Adverse Effect | Management |
|---|---|---|
| ACEi | Dry cough (10-15%) | Switch to ARB |
| ACEi/ARB | Hyperkalemia | Reduce dose, stop potassium supplements, avoid NSAIDs |
| DHP-CCB | Peripheral edema | Add ACEi/ARB (reduces edema), elevate legs, consider switching to ARB + thiazide |
| Thiazide diuretics | Hypokalemia | Add ACEi/ARB or potassium-sparing diuretic, potassium supplementation |
| Beta-blockers | Fatigue, erectile dysfunction | Switch to ACEi/ARB or CCB |
| Spironolactone | Gynecomastia (men) | Switch to eplerenone |
8. HYPERTENSIVE URGENCY VS. EMERGENCY
Hypertensive Urgency
- Definition: Severe BP elevation (≥180/120 mmHg) WITHOUT acute target organ damage 9
- Symptoms: Headache, dizziness, nosebleed (but no chest pain, dyspnea, neurological deficits)
- Management: Oral antihypertensives in OPD; no need for IV therapy or hospitalization 9
- Tab. Amlodipine 10 mg once daily or Tab. Telmisartan 80 mg once daily
- Recheck BP in 1-2 hours; if improving, discharge with close follow-up in 24-48 hours
- Avoid rapid BP reduction (risk of cerebral/myocardial hypoperfusion)
- Target: Reduce BP by 20-25% over 24-48 hours 9
NEVER use short-acting nifedipine sublingual (unpredictable, excessive BP drop, increased stroke/MI risk).
Hypertensive Emergency
- Definition: Severe BP elevation (≥180/120 mmHg) WITH acute target organ damage 9
- Acute organ damage includes:
- Cardiac: Acute coronary syndrome, acute pulmonary edema, acute heart failure
- Neurological: Hypertensive encephalopathy, stroke, intracranial hemorrhage
- Renal: Acute kidney injury
- Vascular: Aortic dissection
- Retinal: Papilledema, retinal hemorrhages
Management: Immediate hospitalization, ICU admission, IV antihypertensive therapy 9.
IV Antihypertensive Drugs for Hypertensive Emergency
| Clinical Scenario | First-Line IV Drug | Dose | BP Reduction Target |
|---|---|---|---|
| Acute pulmonary edema / Acute heart failure | IV Nitroglycerin | 5-10 mcg/min, titrate by 5 mcg/min every 5 min (max 200 mcg/min) | Reduce SBP by 25% in first hour, then to <140 mmHg over 2-6 hours [9] |
| Acute coronary syndrome | IV Nitroglycerin | Same as above | Same as above [9] |
| Aortic dissection | IV Labetalol or IV Esmolol + IV Nitroprusside | Labetalol: 20 mg bolus, then 20-80 mg every 10 min (max 300 mg) OR 0.5-2 mg/min infusion | Reduce SBP to <120 mmHg within 20 minutes [9] |
| Hypertensive encephalopathy | IV Labetalol or IV Nicardipine | Labetalol: Same as above; Nicardipine: 5 mg/hr, titrate by 2.5 mg/hr every 5 min (max 15 mg/hr) | Reduce MAP by 10-20% in first hour, then by additional 5-15% over next 23 hours [9] |
| Acute ischemic stroke | IV Labetalol or IV Nicardipine | Same as above | Do NOT lower BP unless SBP >220 mmHg or DBP >120 mmHg (risk of worsening stroke) [9] |
| Intracerebral hemorrhage | IV Labetalol or IV Nicardipine | Same as above | Reduce SBP to 140-160 mmHg [9] |
Alternative IV Drugs (if above not available in government hospital):
- IV Hydralazine 10-20 mg bolus every 20 minutes (use with caution—unpredictable response)
- IV Enalaprilat 1.25 mg over 5 minutes, repeat every 6 hours (avoid in acute MI)
Referral Criteria for Hypertensive Emergency
Refer IMMEDIATELY to higher center with ICU if:
- Suspected aortic dissection (chest/back pain, BP difference >20 mmHg between arms)
- Acute stroke (neurological deficits)
- Acute MI (chest pain, ECG changes)
- Acute pulmonary edema (severe dyspnea, hypoxia)
- Hypertensive encephalopathy (altered mental status, seizures)
Stabilize with IV antihypertensives during transfer.
9. FOLLOW-UP SCHEDULE, BP MONITORING & DOSE ADJUSTMENT
Follow-Up Schedule
| Clinical Scenario | Follow-Up Interval |
|---|---|
| Newly diagnosed, starting medication | 2-4 weeks (check BP, adherence, side effects) |
| Dose titration or drug addition | 2-4 weeks |
| BP at target, stable | Every 3 months |
| Resistant hypertension | Every 2-4 weeks until controlled, then every 1-3 months |
| High-risk patients (diabetes, CKD, CVD) | Every 1-3 months |
Achieve BP target within 3 months 1, 3. If not achieved, escalate therapy.
Home BP Monitoring
- Recommended for all hypertensive patients (improves adherence, detects white-coat/masked hypertension) 2
- Use validated automated upper arm cuff device
- Measure BP twice daily (morning and evening) for 7 days before each clinic visit
- Home BP target: <135/85 mmHg 1
Treatment Failure: When to Refer
Refer to hypertension specialist if:
- Resistant hypertension (uncontrolled on 4 drugs including spironolactone)
- Suspected secondary hypertension (young age, sudden onset, hypokalemia, abdominal bruit)
- Severe adverse effects from multiple drug classes
- Recurrent hypertensive emergencies
10. PRACTICAL INDIAN GOVERNMENT HOSPITAL OPD PRESCRIPTIONS
Scenario 1: Newly Diagnosed Grade 1 Hypertension (150/95 mmHg), 55-year-old man, Type 2 Diabetes
Diagnosis: Grade 1 Hypertension with diabetes (high-risk) → Start drug therapy immediately 1, 2
Prescription:
1. Tab. Telmisartan 40 mg + Cilnidipine 10 mg (single-pill combination) — 1 tablet once daily after breakfast
2. Tab. Metformin 500 mg — 1 tablet twice daily after meals (for diabetes)
3. Lifestyle modifications: Low-salt diet (<5 g/day), 30 min brisk walk daily, weight loss
Follow-up: 4 weeks (check BP, fasting glucose, HbA1c, serum creatinine, potassium)
Target BP: <130/80 mmHgRationale: ACEi/ARB + DHP-CCB is first-line for diabetic hypertension 2, 4. Cilnidipine offers additional renoprotection 2, 4.
Scenario 2: Grade 2 Hypertension (170/105 mmHg), 60-year-old woman, No Comorbidities
Diagnosis: Grade 2 Hypertension → Start dual combination therapy immediately 1, 5
Prescription:
1. Tab. Telmisartan 40 mg + Amlodipine 5 mg (single-pill combination) — 1 tablet once daily after breakfast
2. Lifestyle modifications: Low-salt diet, DASH diet, 30 min exercise daily
Follow-up: 4 weeks (check BP, serum creatinine, potassium)
Target BP: <140/90 mmHg
If BP not controlled at 4 weeks:
Increase to Tab. Telmisartan 80 mg + Amlodipine 10 mg once dailyRationale: Dual combination therapy achieves faster BP control and improves adherence 5, 3.
Scenario 3: Uncontrolled Hypertension (155/95 mmHg) on Telmisartan 80 mg + Amlodipine 10 mg
Diagnosis: Inadequate BP control on dual therapy → Add third drug 1, 3
Prescription:
1. Tab. Telmisartan 80 mg + Amlodipine 10 mg — 1 tablet once daily after breakfast
2. Tab. Chlorthalidone 12.5 mg — 1 tablet once daily in the morning
3. Continue lifestyle modifications
Follow-up: 4 weeks (check BP, serum creatinine, potassium, sodium)
Target BP: <140/90 mmHgRationale: Triple therapy with RAS blocker + CCB + thiazide-like diuretic is standard 1, 3.
Scenario 4: Resistant Hypertension (160/100 mmHg) on Triple Therapy
Diagnosis: Resistant hypertension → Add spironolactone 1, 3
Prescription:
1. Tab. Telmisartan 80 mg + Amlodipine 10 mg + Chlorthalidone 12.5 mg — Continue
2. Tab. Spironolactone 25 mg — 1 tablet once daily in the morning
3. Check medication adherence, confirm with home BP monitoring
Follow-up: 1 week (check serum potassium), then 4 weeks (check BP, creatinine, potassium)
Target BP: <140/90 mmHg
If potassium >5.5 mEq/L: Stop spironolactone, refer to specialistRationale: Spironolactone is highly effective in resistant hypertension 1, 3. Close potassium monitoring is essential.
Scenario 5: Post-MI Patient with Hypertension (145/90 mmHg)
Diagnosis: Hypertension with CAD (post-MI) → Beta-blocker + ACEi mandatory 6
Prescription:
1. Tab. Metoprolol succinate 50 mg — 1 tablet once daily after breakfast
2. Tab. Ramipril 5 mg — 1 tablet once daily after breakfast
3. Tab. Aspirin 75 mg — 1 tablet once daily after dinner
4. Tab. Atorvastatin 40 mg — 1 tablet once daily at bedtime
5. Lifestyle modifications
Follow-up: 4 weeks (check BP, heart rate, serum creatinine, potassium, lipid profile)
Target BP: <130/80 mmHgRationale: Beta-blocker + ACEi reduce mortality post-MI 6.
Scenario 6: CKD Stage 3 (eGFR 45 mL/min) with Hypertension (150/95 mmHg)
Diagnosis: Hypertension with CKD → ACEi/ARB for renoprotection 6
Prescription:
1. Tab. Ramipril 5 mg — 1 tablet once daily after breakfast
2. Tab. Amlodipine 5 mg — 1 tablet once daily after breakfast
3. Low-salt diet, avoid NSAIDs
Follow-up: 2 weeks (check serum creatinine, potassium), then 4 weeks (check BP)
Target BP: <130/80 mmHg
Accept up to 30% rise in creatinine. If creatinine rises >30%, reduce Ramipril dose or refer.Rationale: ACEi/ARB slow CKD progression 6. Close monitoring for hyperkalemia and acute kidney injury is essential.
Scenario 7: Elderly Patient (Age 82 years), Frail, BP 165/90 mmHg
Diagnosis: Hypertension in elderly, frail patient → Start monotherapy, less stringent target 1, 3
Prescription:
1. Tab. Amlodipine 2.5 mg — 1 tablet once daily after breakfast
2. Lifestyle modifications (low-salt diet, gentle walking)
Follow-up: 4 weeks (check BP sitting and standing, assess for dizziness/falls)
Target BP: <150/90 mmHg
If tolerated and BP not controlled, increase to Amlodipine 5 mg after 4 weeks.Rationale: Elderly and frail patients require slower titration and less stringent BP targets to avoid orthostatic hypotension and falls 1, 3.
COMMON INDIAN DRUG COMBINATIONS & INDICATIONS
Single-Pill Combinations (SPCs) Available in India
SPCs improve adherence and BP control 3. Preferred over free-pill combinations.
| Combination | Indication | Example Brand (Generic) |
|---|---|---|
| Telmisartan + Amlodipine | First-line dual therapy for most patients | Telma-AM, Telmikind-AM |
| Telmisartan + Chlorthalidone | Dual therapy, especially if edema with CCB | Telma-CT, Telmikind-CT |
| Telmisartan + Cilnidipine | Diabetic hypertension (renoprotection) [2,4] | Telma-CL, Telmikind-CL |
| Ramipril + Amlodipine | First-line dual therapy | Cardace-AM, Ramipres-AM |
| Losartan + Amlodipine | First-line dual therapy | Losar-AM, Losium-AM |
| Telmisartan + Amlodipine + Chlorthalidone | Triple therapy | Telma-AMH, Telmikind-AMH |
| Olmesartan + Amlodipine + Chlorthalidone | Triple therapy | Olmy-Trio |
Rationale: SPCs reduce pill burden, improve adherence, and achieve faster BP control 3.
DANGEROUS PRESCRIBING MISTAKES TO AVOID
Combining ACEi + ARB: Increases harm without additional benefit 5, 3. NEVER do this.
Using short-acting nifedipine sublingual for hypertensive urgency: Unpredictable, excessive BP drop, increased stroke/MI risk. Use extended-release formulations only.
Starting spironolactone without checking potassium: Risk of life-threatening hyperkalemia, especially with ACEi/ARB. Always check potassium at 1 week.
Prescribing ACEi/ARB in pregnancy: Teratogenic. Absolutely contraindicated. Use methyldopa, labetalol, or nifedipine.
Rapid BP reduction in hypertensive urgency: Risk of cerebral/myocardial hypoperfusion. Reduce BP by 20-25% over 24-48 hours, not minutes.
Ignoring orthostatic hypotension in elderly: Increases fall risk. Always measure BP sitting and standing.
Using thiazide diuretics in severe CKD (eGFR <30 mL/min): Ineffective. Switch to loop diuretics (furosemide).
Prescribing NSAIDs with ACEi/ARB + diuretic ("Triple Whammy"): High risk of acute kidney injury. Avoid NSAIDs; use paracetamol for pain.
Not checking creatinine and potassium after starting ACEi/ARB: Risk of missing hyperkalemia or acute kidney injury. Check at 1-2 weeks.
Treating hypertensive urgency as emergency: Unnecessary hospitalization, IV therapy, and costs. Manage with oral antihypertensives in OPD unless acute organ damage present.
GUIDELINE RECOMMENDATIONS VS. LOCAL INDIAN PRACTICE
Guideline Recommendations (ISH 2020, ESC 2024, AHA/ACC 2025):
- Initial combination therapy for most patients with Grade 2 hypertension or high-risk Grade 1 hypertension 5, 3
- Single-pill combinations (SPCs) preferred over free-pill combinations 3
- Chlorthalidone or indapamide preferred over HCTZ 5
- Beta-blockers NOT first-line unless compelling indication 3
Local Indian Practice (Often Diverges from Guidelines):
- Monotherapy still commonly used as initial treatment (therapeutic inertia) 10
- Free-pill combinations more common than SPCs (cost, availability) 10
- HCTZ more commonly prescribed than chlorthalidone (availability in government hospitals) 10
- Beta-blockers (atenolol) still frequently used as first-line (outdated practice) 10
Recommendation: Follow international guidelines (ISH 2020, ESC 2024) for better outcomes 1, 5, 3. Use SPCs when available, start with combination therapy for Grade 2 hypertension, and reserve beta-blockers for compelling indications.
This algorithm is based on the 2020 ISH Global Hypertension Practice Guidelines 1, 2024 ESC Guidelines 3, and 2025 AHA/ACC Guidelines 5, adapted for the Indian government hospital OPD setting with practical prescriptions and common pitfalls highlighted.